TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT02588625

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Cause of deathNo reason given Automatic label, confidence 0.9, unverified. How labels are made.

The sponsor gave no reason.

Life of this trial

201520162017Registered2015-10-26Planned start2016-02 (planned)Withdrawn (as of)2016-07-22

Vital statistics

Status
Withdrawn
Phase
Phase 2
Sponsor
Bristol-Myers Squibb
Sponsor type
Industry
Conditions
Scleroderma
Interventions
BMS-986020; Placebo
Participants
0
Sites
27
Countries
Canada, Poland, United Kingdom, United States

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.